Skip to main content

Advertisement

SpringerLink
Log in

What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?

  • Chronic Myeloid Leukemias (G Saglio, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers.

Recent Findings

CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer have more heterogeneous phenotypes and extraordinarily greater genotypic diversity and mutational complexity.

Summary

Lesions learned from treating CML have little applicability to other leukaemias, haematologic cancers or solid cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. By cure we mean having a life-expectancy like age- and sex-matched persons without CML.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7 Normal survival of Swedes with CML.

    Article  CAS  Google Scholar 

  2. Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.

    Article  CAS  Google Scholar 

  3. • Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlman R, Jiang Q, et al. Do persons with chronic myeloid leukaemia really have normal survival? Leukemia. 2019. Decreased survival of US persons with CML.

  4. Gambacorti-Passerini C, Antolini L, Mahon, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–61.

    Article  CAS  Google Scholar 

  5. • Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multi-centre, non-randomized trial. Lancet Oncol. 2018;19:747–57 Large trial of therapy-free remission.

    Article  CAS  Google Scholar 

  6. Saglio G, Gale RP. Prospects for achieving therapy-free remission in chronic myeloid leukaemia. Br J Haematol In press.

  7. Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447–59.

    Article  Google Scholar 

  8. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56.

    Article  CAS  Google Scholar 

  9. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210/abl gene of the Philadelphia chromosome. Science. 1990;24:824–30.

    Article  Google Scholar 

  10. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.

    Article  Google Scholar 

  11. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25.

    Article  Google Scholar 

  12. The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. doi https://doi.org/10.1016/j.Cell.2015.10.025.

    Article  CAS  Google Scholar 

  13. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

    Article  Google Scholar 

  14. Preisler H, Raza A. An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system. Leuk Lymphoma. 1993;11(Suppl 1):145–50.

    Article  Google Scholar 

  15. Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydio R, et al. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors. Haematologica. 2019. https://doi.org/10.3324/haematol.2018.200220.

    Article  Google Scholar 

  16. • Branford S, Kim DDH, Apperley JF, Edie CA, Mustjoki S, Ong ST. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33:1835–50 A review of the impact of mutations other than BCRABL1 on prognosis of persons with CML.

    Article  Google Scholar 

  17. • Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17:49 The impact of BCRABL1 detection on therapy outcomes.

    Article  Google Scholar 

  18. Houshmand M, Simoneti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33:1543–56.

    Article  CAS  Google Scholar 

  19. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53–61. https://doi.org/10.1182/blood-2015-08-604520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  21. Bejar R. CHIP, ICUS, CCUS and other four-letter words. Leukemia. 2017;31:1869–71.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Inflammation, Centre for Haematology Research, Imperial College London, London, SW7 2AZ, UK

    Robert Peter Gale & Jane Apperley

Authors
  1. Robert Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Peter Gale.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Topical Collection on Chronic Myeloid Leukemias

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gale, R.P., Apperley, J. What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?. Curr Hematol Malig Rep 14, 477–479 (2019). https://doi.org/10.1007/s11899-019-00555-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-019-00555-3

Keywords

Search

Navigation